X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-05-20 | REPL | Astley-Sparke Philip | Dir | S - Sale | $8.06 | -32,279 | 1,405,071 | -2% | -$260,169 | ||||||
2025-05-20 | REPL | Xynos Konstantinos | Chief Medical Officer | S - Sale | $8.06 | -7,952 | 146,933 | -5% | -$64,093 | ||||||
2025-05-20 | REPL | Schwendenman Andrew | Chief Accounting Officer | S - Sale | $8.05 | -3,287 | 68,284 | -5% | -$26,460 | ||||||
2025-05-20 | REPL | Patel Sushil | CEO | S - Sale | $8.06 | -25,105 | 343,576 | -7% | -$202,346 | ||||||
2025-05-20 | REPL | Hill Emily Luisa | CFO | S - Sale | $8.05 | -2,535 | 143,522 | -2% | -$20,407 | ||||||
2025-05-20 | REPL | Sarchi Christopher | Chief Commercial Officer | S - Sale | $8.05 | -3,749 | 128,296 | -3% | -$30,179 | ||||||
2024-12-16 | REPL | Patel Sushil | CEO | S - Sale | $12.42 | -10,000 | 202,014 | -5% | -$124,200 | ||||||
2024-11-18 | REPL | Xynos Konstantinos | Chief Medical Officer | S - Sale | $10.78 | -7,246 | 109,885 | -6% | -$78,112 | ||||||
2024-11-18 | REPL | Sarchi Christopher | Chief Commercial Officer | S - Sale | $10.78 | -5,207 | 87,045 | -6% | -$56,131 | ||||||
2024-08-16 | REPL | Hill Emily Luisa | CFO | S - Sale | $10.18 | -8,938 | 101,057 | -8% | -$90,989 | ||||||
2024-06-07 | REPL | Xynos Konstantinos | Chief Medical Officer | S - Sale | $7.50 | -15,881 | 117,131 | -12% | -$119,108 | ||||||
2024-05-16 | REPL | Sarchi Christopher | Chief Commercial Officer | S - Sale | $6.47 | -2,218 | 92,252 | -2% | -$14,350 | ||||||
2024-05-16 | REPL | Schwendenman Andrew | Chief Accounting Officer | S - Sale | $6.47 | -2,298 | 38,238 | -6% | -$14,868 | ||||||
2024-05-16 | REPL | Love Colin | COO | S - Sale | $6.47 | -17,615 | 777,345 | -2% | -$113,969 | ||||||
2024-05-16 | REPL | Astley-Sparke Philip | Exec COB | S - Sale | $6.47 | -37,928 | 1,487,350 | -2% | -$245,394 | ||||||
2024-05-16 | REPL | Coffin Robert | Dir | S - Sale | $6.47 | -11,464 | 1,821,872 | -1% | -$74,172 | ||||||
2024-05-16 | REPL | Patel Sushil | CEO | S - Sale | $6.47 | -20,194 | 212,014 | -9% | -$130,655 | ||||||
2024-05-16 | REPL | Xynos Konstantinos | Chief Medical Officer | S - Sale | $6.47 | -6,367 | 133,012 | -5% | -$41,194 | ||||||
2023-11-16 | REPL | Xynos Konstantinos | Chief Medical Officer | S - Sale | $10.92 | -7,313 | 112,714 | -6% | -$79,858 | ||||||
2023-11-16 | REPL | Sarchi Christopher | Chief Commercial Officer | S - Sale | $10.92 | -5,255 | 72,245 | -7% | -$57,385 | ||||||
| DM | 2023-09-11 | REPL | Esposito Pamela | Chief Business Officer | S - Sale+OE | $20.01 | -5,658 | 263,436 | -2% | -$113,214 | |||||
| D | 2023-08-22 | REPL | Esposito Pamela | Chief Business Officer | S - Sale+OE | $20.01 | -18,600 | 263,436 | -7% | -$372,186 | |||||
| D | 2023-08-11 | REPL | Esposito Pamela | Chief Business Officer | S - Sale+OE | $20.00 | -1,400 | 263,436 | -1% | -$28,000 | |||||
| D | 2023-07-10 | REPL | Esposito Pamela | Chief Business Officer | S - Sale+OE | $21.58 | -20,000 | 263,436 | -7% | -$431,541 | |||||
2023-06-13 | REPL | Lewis Tanya | Chief Dev. Op. Officer | S - Sale | $24.06 | -12,860 | 135,293 | -9% | -$309,395 | ||||||
2023-06-13 | REPL | Patel Sushil | Chief Strategy Officer | S - Sale | $24.05 | -5,698 | 148,873 | -4% | -$137,008 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |